2/4
08:15 am
holx
Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio
Low
Report
Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio
1/30
07:12 pm
holx
HOLX Stock Slips on Q1 Earnings and Revenue Miss, Margins Crash [Yahoo! Finance]
Low
Report
HOLX Stock Slips on Q1 Earnings and Revenue Miss, Margins Crash [Yahoo! Finance]
1/30
06:06 am
holx
Hologic (NASDAQ:HOLX) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Hologic (NASDAQ:HOLX) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
1/29
04:02 pm
holx
Hologic Announces Financial Results for First Quarter of Fiscal 2026
Low
Report
Hologic Announces Financial Results for First Quarter of Fiscal 2026
1/23
04:36 pm
holx
Analysts consider potential Qiagen deal amid reported strategic review [Yahoo! Finance]
Low
Report
Analysts consider potential Qiagen deal amid reported strategic review [Yahoo! Finance]
1/19
06:16 pm
holx
Hologic, Inc. (HOLX): A Bear Case Theory [Yahoo! Finance]
Low
Report
Hologic, Inc. (HOLX): A Bear Case Theory [Yahoo! Finance]
1/19
10:10 am
holx
Pop-Up Clinics Increasing Access to Cervical Cancer Screenings this Cervical Health Awareness Month [Yahoo! Finance]
Low
Report
Pop-Up Clinics Increasing Access to Cervical Cancer Screenings this Cervical Health Awareness Month [Yahoo! Finance]
1/15
07:00 pm
holx
Hologic to Announce Financial Results for the First Quarter of Fiscal 2026 on Thursday, January 29, 2026
Low
Report
Hologic to Announce Financial Results for the First Quarter of Fiscal 2026 on Thursday, January 29, 2026
1/13
09:00 am
holx
Professional Basketball Player Erica Wheeler and Hologic Team Up to Champion Cervical Cancer Screening
Low
Report
Professional Basketball Player Erica Wheeler and Hologic Team Up to Champion Cervical Cancer Screening
1/12
09:18 am
holx
Hologic (NASDAQ:HOLX) was downgraded by analysts at Argus from a "buy" rating to a "hold" rating.
Low
Report
Hologic (NASDAQ:HOLX) was downgraded by analysts at Argus from a "buy" rating to a "hold" rating.
1/8
11:51 am
holx
Halper Sadeh LLC Encourages HOLX, VTYX, QRVO, TEX Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages HOLX, VTYX, QRVO, TEX Shareholders to Contact the Firm to Discuss Their Rights
1/7
05:13 pm
holx
Hologic Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Hologic, Inc. - HOLX
Low
Report
Hologic Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Hologic, Inc. - HOLX
1/5
09:00 am
holx
Hologic (NASDAQ:HOLX) was downgraded by analysts at Evercore ISI from an "outperform" rating to an "inline" rating. They now have a $78.00 price target on the stock.
Low
Report
Hologic (NASDAQ:HOLX) was downgraded by analysts at Evercore ISI from an "outperform" rating to an "inline" rating. They now have a $78.00 price target on the stock.
12/23
06:56 pm
holx
Halper Sadeh LLC Encourages SNCR, HOLX, FRGE Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages SNCR, HOLX, FRGE Shareholders to Contact the Firm to Discuss Their Rights
12/16
08:54 am
holx
Hologic's AI-Powered Mammography Technology Flagged a Third of Breast Cancer Cases Initially Interpreted as Negative in Study of 7,500 Screening Exams [Yahoo! Finance]
Low
Report
Hologic's AI-Powered Mammography Technology Flagged a Third of Breast Cancer Cases Initially Interpreted as Negative in Study of 7,500 Screening Exams [Yahoo! Finance]
12/16
08:08 am
holx
Hologic’s AI-Powered Mammography Technology Flagged a Third of Breast Cancer Cases Initially Interpreted as Negative in Study of 7,500 Screening Exams
Low
Report
Hologic’s AI-Powered Mammography Technology Flagged a Third of Breast Cancer Cases Initially Interpreted as Negative in Study of 7,500 Screening Exams
12/2
08:10 am
holx
New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test, the Leading Biomarker in Personalizing Endocrine Therapy Duration
Low
Report
New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test, the Leading Biomarker in Personalizing Endocrine Therapy Duration
12/1
10:24 am
holx
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It [Yahoo! Finance]
Low
Report
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It [Yahoo! Finance]
11/25
08:08 am
holx
New Clinical Evidence on Hologic’s AI-Powered Mammography Solutions Will Be Unveiled at RSNA
Low
Report
New Clinical Evidence on Hologic’s AI-Powered Mammography Solutions Will Be Unveiled at RSNA
11/21
05:30 pm
holx
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-HOLX, MOFG, NIC, and AWK
Low
Report
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-HOLX, MOFG, NIC, and AWK
11/21
08:13 am
holx
Hologic (NASDAQ:HOLX) was downgraded by analysts at BNP Paribas Exane from an "outperform" rating to a "neutral" rating. They now have a $79.00 price target on the stock.
Low
Report
Hologic (NASDAQ:HOLX) was downgraded by analysts at BNP Paribas Exane from an "outperform" rating to a "neutral" rating. They now have a $79.00 price target on the stock.
11/21
06:04 am
holx
Hologic (NASDAQ:HOLX) was downgraded by analysts at BNP Paribas to a "neutral" rating.
Low
Report
Hologic (NASDAQ:HOLX) was downgraded by analysts at BNP Paribas to a "neutral" rating.
11/12
07:10 pm
holx
Hologic Introduces Digital Pathology Capabilities With Expanded CE Marking [Yahoo! Finance]
Low
Report
Hologic Introduces Digital Pathology Capabilities With Expanded CE Marking [Yahoo! Finance]
11/12
08:11 am
holx
Hologic Introduces Digital Pathology Capabilities With Expanded CE Marking
Low
Report
Hologic Introduces Digital Pathology Capabilities With Expanded CE Marking
11/11
12:21 pm
holx
Hologic (NASDAQ:HOLX) had its price target raised by analysts at Morgan Stanley from $69.00 to $76.00. They now have an "equal weight" rating on the stock.
Low
Report
Hologic (NASDAQ:HOLX) had its price target raised by analysts at Morgan Stanley from $69.00 to $76.00. They now have an "equal weight" rating on the stock.